Modified virus tested to attack tough esophageal cancers

NCT ID NCT04391049

Summary

This early-stage study is testing the safety of adding a specially designed virus (OBP-301) to standard chemotherapy and radiation for patients with advanced esophageal or gastroesophageal cancer who are not candidates for surgery. The virus is meant to infect and kill cancer cells. The main goal is to see if this three-part combination is safe and tolerable for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • City of Hope South Pasadena

    South Pasadena, California, 91030, United States

  • City of Hope Upland

    Upland, California, 91786, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Kansas Clinical Research Center

    Fairway, Kansas, 66205, United States

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas, 66205, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED ESOPHAGEAL ADENOCARCINOMA ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE IIA ESOPHAGEAL ADENOCARCINOMA AJCC V8 CLINICAL STAGE IIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE IIB ESOPHAGEAL ADENOCARCINOMA AJCC V8 CLINICAL STAGE IIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIA ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIB ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIB ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIB ESOPHAGEAL ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 SQUAMOUS CELL CANCER SQUAMOUS CELL CARCINOMA UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA